ИСТИНА

Beta-lactam antibiotics represent the most widely used group of antibacterial agents with broad-spectrum activity. However, bacteria can develop antibiotic resistance, often mediated by beta-lactamases. These enzymes render antibiotics inactive through the hydrolysis of the beta-lactam ring, resulting in the degradation of the drug. This process can be inhibited, but due to frequent mutations in the active site of the enzyme, inhibitors become ineffective at an accelerating rate. Thus, the identification of alternative means of beta-lactamase inhibition and the development of improved inhibitors is a priority.